Lesley Russell M.B.Ch.B, MRCP
Chief Operating Officer
Dr. Russell is currently the Chief Operating Officer of TetraLogic Pharmaceuticals. Prior to TetraLogic, Dr. Russell served as senior vice president and head of research and development for global branded products at Teva Pharmaceuticals. She was appointed to this role upon Teva's acquisition of Cephalon, Inc., where she served as executive vice president and chief medical officer. Dr. Russell joined Cephalon in 2000 and held various positions of increasing responsibility, including head of clinical research and medical affairs, prior to becoming Cephalon’s chief medical officer in September 2006. During her tenure at Cephalon, Dr. Russell filed multiple NDAs to the FDA and marketing authorization applications (MAAs) to the Committee for Medicinal Products for Human Use (CHMP). Before joining Cephalon, Dr. Russell held positions of increasing responsibility at Amgen U.K., Lilly Industries, U.K., and U.S. Bioscience, now acquired by MedImmune Oncology. Dr. Russell received a M.B.Ch.B. degree from the University of Edinburgh, Scotland. She is a member of the Royal College of Physicians, U.K., and is registered with the General Medical Council, U.K. She currently serves as a member of the board of directors of AMAG Pharma, a company traded on NASDAQ.